Search - tctmd.com

Displaying 1 - 20 of 137

Sort: Relevancy | Date

Despite Guidelines, Aspirin Is Used in Fewer Than One in Four High-risk Pregnancies

News Conference News ACC 2026

Despite Guidelines, Aspirin Is Used in Fewer Than One in Four High-risk Pregnancies

Yael L. Maxwell

April 03, 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

News Conference News ACC 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Yael L. Maxwell

April 01, 2026

GoFreshRx, THRIVE Trials Show BP Benefits of ‘Food as Medicine’

News Conference News ACC 2026

GoFreshRx, THRIVE Trials Show BP Benefits of ‘Food as Medicine’

March 31, 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

News Conference News ACC 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Michael O'Riordan

March 30, 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

News Conference News ACC 2026

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

March 28, 2026

What’s Going to Be Hot at ACC 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

April 03, 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

April 16, 2024

HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players

News Conference News ACC 2024

HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players

Michael O'Riordan

April 15, 2024

Vaping Linked to Higher Risk of HFpEF, NIH Data Show

News Conference News ACC 2024

Vaping Linked to Higher Risk of HFpEF, NIH Data Show

April 12, 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

News Conference News ACC 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

April 11, 2024

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

News Conference News ACC 2024

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

April 11, 2024

Need a Statin for Primary Prevention? There’s an App for That

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.